Krisy-Ann Thornby1, Ashley Johnson2, Samantha Axtell2. 1. Palm Beach Atlantic University, West Palm Beach, FL, USA krisy_thornby@pba.edu. 2. Palm Beach Atlantic University, West Palm Beach, FL, USA.
Abstract
OBJECTIVE: To review the literature evaluating the efficacy of dornase alfa for non-cystic fibrosis pediatric patients with pulmonary atelectasis. DATA SOURCES: Articles were retrieved after a search of MEDLINE/PubMed (1946 to April 2014), and International Pharmaceutical Abstracts (1970-April 2014) was performed using the terms dornase alfa, recombinant human deoxyribonuclease, pulmonary, persistent, and atelectasis. Other relevant articles referenced from the MEDLINE search were also utilized. STUDY SELECTION AND DATA EXTRACTION: Data sources were limited to English language clinical trials and case studies including only children; 8 clinical trials and 12 case reports met the criteria. DATA SYNTHESIS: Dornase alfa is used as an off-label treatment option for pulmonary atelectasis because limited treatment modalities exist after conventional therapy has failed. We evaluated 8 clinical trials and 12 case reports involving this pediatric population with varying primary diagnoses. The majority of patients experienced improvement in atelectasis, suggesting benefit after receiving treatment with dornase alfa. However, the outcomes were possibly confounded by those receiving combination therapies, varying primary diagnoses, and varying end points evaluated. Dornase alfa was overall well tolerated, with only a few patients experiencing worsening atelectasis posttreatment. CONCLUSIONS: Dornase alfa may be considered as a therapeutic option in non-cystic fibrosis pediatric patients with pulmonary atelectasis, who require treatment intervention when conventional therapy is unsuccessful.
OBJECTIVE: To review the literature evaluating the efficacy of dornase alfa for non-cystic fibrosis pediatricpatients with pulmonary atelectasis. DATA SOURCES: Articles were retrieved after a search of MEDLINE/PubMed (1946 to April 2014), and International Pharmaceutical Abstracts (1970-April 2014) was performed using the terms dornase alfa, recombinant human deoxyribonuclease, pulmonary, persistent, and atelectasis. Other relevant articles referenced from the MEDLINE search were also utilized. STUDY SELECTION AND DATA EXTRACTION: Data sources were limited to English language clinical trials and case studies including only children; 8 clinical trials and 12 case reports met the criteria. DATA SYNTHESIS: Dornase alfa is used as an off-label treatment option for pulmonary atelectasis because limited treatment modalities exist after conventional therapy has failed. We evaluated 8 clinical trials and 12 case reports involving this pediatric population with varying primary diagnoses. The majority of patients experienced improvement in atelectasis, suggesting benefit after receiving treatment with dornase alfa. However, the outcomes were possibly confounded by those receiving combination therapies, varying primary diagnoses, and varying end points evaluated. Dornase alfa was overall well tolerated, with only a few patients experiencing worsening atelectasis posttreatment. CONCLUSIONS:Dornase alfa may be considered as a therapeutic option in non-cystic fibrosis pediatricpatients with pulmonary atelectasis, who require treatment intervention when conventional therapy is unsuccessful.
Authors: Rayan S Terkawi; Khaild A Altirkawi; Abdullah S Terkawi; Gawahir Mukhtar; Abdullah Al-Shamrani Journal: Int J Pediatr Adolesc Med Date: 2016-01-28